[{"address1": "3710 \u2013 33rd Street NW", "city": "Alberta Beach", "state": "AB", "zip": "T2L 2M1", "country": "Canada", "phone": "(403) 455-7727", "website": "https://www.xortx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.", "fullTimeEmployees": 2, "maxAge": 86400, "priceHint": 4, "previousClose": 2.06, "open": 2.0838, "dayLow": 2.08, "dayHigh": 2.2, "regularMarketPreviousClose": 2.06, "regularMarketOpen": 2.0838, "regularMarketDayLow": 2.08, "regularMarketDayHigh": 2.2, "beta": -0.131, "forwardPE": -1.257485, "volume": 4831, "regularMarketVolume": 4831, "averageVolume": 15843, "averageVolume10days": 8940, "averageDailyVolume10Day": 8940, "marketCap": 6173957, "fiftyTwoWeekLow": 1.9, "fiftyTwoWeekHigh": 67.716, "fiftyDayAverage": 2.60118, "twoHundredDayAverage": 10.95741, "currency": "USD", "enterpriseValue": 2276083, "floatShares": 2642128, "sharesOutstanding": 2903560, "sharesShort": 3392, "sharesShortPriorMonth": 8474, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0011999999, "heldPercentInsiders": 0.0332, "heldPercentInstitutions": 0.06422, "shortRatio": 0.22, "shortPercentOfFloat": 0.0011999999, "bookValue": 0.858, "priceToBook": 2.4475524, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -3344966, "trailingEps": -1.38, "forwardEps": -1.67, "enterpriseToEbitda": -0.587, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "XRTX", "underlyingSymbol": "XRTX", "shortName": "XORTX Therapeutics Inc.", "longName": "XORTX Therapeutics Inc.", "firstTradeDateEpochUtc": 1632403800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ccf511eb-7240-3e07-af90-4d0cc6586c46", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.1, "targetHighPrice": 14.01, "targetLowPrice": 10.31, "targetMeanPrice": 12.15, "targetMedianPrice": 12.15, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 2, "totalCash": 3835440, "totalCashPerShare": 1.321, "ebitda": -3874992, "totalDebt": 14037, "quickRatio": 11.341, "currentRatio": 13.676, "debtToEquity": 0.563, "returnOnAssets": -0.31002, "returnOnEquity": -0.57921004, "freeCashflow": -2958249, "operatingCashflow": -5401830, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]